Abstract
Previous studies have established the anticancer effect of vitamin K2 (VK2). However, its effect on lymphoma induced by UBIAD1/heix mutation in Drosophila remains unknown. Therefore, we aimed to develop an in vivo model of lymphoma for the precise characterization of lymphoma phenotypes. We also aimed to improve the understanding of the mechanisms that underlie the preventative effects of VK2 on lymphoma. Our results demonstrated that VK2 prevents lymphoma by acting as an electron carrier and by correcting the function and structure of mitochondria by inhibiting mitochondrial reactive oxygen species production mtROS. Our work identifies mitochondria as a key player in cancer therapy strategies.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenosine Triphosphate / metabolism
-
Animals
-
Dimethylallyltranstransferase / genetics
-
Dimethylallyltranstransferase / metabolism
-
Disease Models, Animal
-
Drosophila / growth & development
-
Drosophila / metabolism
-
Drosophila Proteins / genetics
-
Drosophila Proteins / metabolism
-
Larva / drug effects
-
Larva / metabolism
-
Lymphoma / metabolism
-
Lymphoma / pathology
-
Lymphoma / prevention & control*
-
Membrane Potential, Mitochondrial / drug effects
-
Mitochondria / drug effects
-
Mitochondria / metabolism
-
Reactive Oxygen Species / metabolism
-
Vitamin K 2 / pharmacology
-
Vitamin K 2 / therapeutic use*
Substances
-
Drosophila Proteins
-
Reactive Oxygen Species
-
Vitamin K 2
-
Adenosine Triphosphate
-
Dimethylallyltranstransferase